Boehringer Ingelheim program for treatment of schizophrenia

Saniona entered into a drug discovery and development collaboration with Boehringer Ingelheim in 2016. The collaboration focuses on research of new small molecule therapeutics that could be capable of restoring brain network activity in patients with schizophrenia. By combining Saniona’s expertise in ion channels and related technology platforms with Boehringer Ingelheim’s expertise in research and clinical development as well as marketing of medicines, we are well positioned to advance new treatment options for schizophrenia. Saniona will receive research funding during the joint research period and up to €90 million in milestone payments. Furthermore, Saniona is eligible to receive royalties on worldwide net sales of any resulting products under the collaboration.

In July 2018, Boehringer Ingelheim selected the first candidate for preclinical and clinical development under Saniona’s and Boehringer Ingelheim’s collaboration.

The program is in the preclinical development phase.

Boehringer Ingelheim GmbH (“Boehringer Ingelheim”), founded in 1885, is one of the world’s 20 leading pharmaceutical companies. The focus of the family-owned company is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.